Clinical Trial Update: Safety, Efficacy and Pharmacokinetics (PK) Study of WR 279,396 Versus Paromomycin for Treatment of Cutaneous Leishmaniasis (Peru-PK) [Phase 2]

View source ↗

Summary

Phase 2 study comparing WR-279,396 to paromomycin for cutaneous leishmaniasis evaluating safety, efficacy, and pharmacokinetics; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Leishmaniasis

Drugs mentioned

• Paromomycin (paromomycin)
• WR 279,396

Snippet

Sponsor: U.S. Army Medical Research and Development Command | Conditions: Leishmaniasis, Cutaneous | Phase 2 | Status: COMPLETED | Results posted: 2014-08-22